The U.S. Food and Drug Administration (FDA) approved Dojolvi on June 30, 2020, for the treatment of long-chain fatty acid oxidation disorders (LC-FAODs) in adults and children.

Elicio Therapeutics Presents Initial Disease-Free Survival Data from the Phase 1a AMPLIFY-7P Study of ELI-002 7P.

The U.S. Food and Drug Administration (FDA) approved Phesgo on June 29, 2020, for the treatment of HER2-positive breast cancer.

Ensho Therapeutics revealed that it has secured a portfolio of oral α4β7 integrin inhibitors under an exclusive global license agreement with EA Pharma Co., Ltd., a division of Eisai Co., Ltd.

The U.S. Food and Drug Administration (FDA) approved fenfluramine on June 25, 2020, for the treatment of seizures associated with Dravet syndrome in patients two years of age and older.

Elevation Oncology Unveils New Strategy for EO-3021 in Gastric and Gastroesophageal Junction Cancer Patients.

The U.S. Food and Drug Administration (FDA) granted accelerated approval to lurbinectedin on June 15, 2020.

Bicara Therapeutics Announces New Interim Phase 1/1b Data for Ficerafusp Alfa (BCA101) in First-Line HPV-negative Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC).

Jul 2nd latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

Meitheal Pharmaceuticals has obtained exclusive U.S. commercial rights for YUSIMRY, a biosimilar to Humira.

The U.S. Food and Drug Administration (FDA) approved inebilizumab on June 11, 2020.

CASI Pharmaceuticals Plans IND Submission for CID-103 in Antibody-Mediated Rejection and Receives Non-Binding Offer to Acquire Its China Operations.